An observational study in Patients With Uncertain Difficult Airway, Colon Cancer and Gastric Cancer, sponsored by RenJi Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-14.
Sponsored by RenJi Hospital · Observational
This study would explore the safety and feasibility of a reversible induction strategy for uncertain difficult airway. This reversible induction strategy would include high flow nasal canular oxygenation support, short-term effect anesthetic including Propofol and Remifentanil for sedation and analgesia and Sugammadex would be used for reverse the muscle relaxant.
6,367 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's planned enrollment of 20 is below the median of 200 across 1,179 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with an uncertain difficult airway, who will undergo a selective operation and need trachea intubtion.
Exclusion Criteria:
Successful rate of reversion
Time frame: From the beginning of induction to 15min later
TOFr 0.9 reversion time
Time frame: From the beginning of induction to 15min later
BIS 80 reversion time
Time frame: From the beginning of induction to 15min later
Tidal volume 6-8ml tidal volume 6-8ml/kg reversion time
Time frame: From the beginning of induction to 15min later
consciousness reversion time
Time frame: From the beginning of induction to 15min later
Plan to share: No — IPD is unavailable to other researchers
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RenJi Hospital